Short-Term and Long-Term Oncological Outcomes of Chemoradiotherapy for Rectal Cancer Patients With or Without Oxaliplatin: A Propensity Score-Matched Retrospective Analysis

Short-Term and Long-Term Oncological Outcomes of Chemoradiotherapy for Rectal Cancer Patients With or Without Oxaliplatin: A Propensity Score-Matched Retrospective Analysis Publisher Pubmed

Azimi A¹ ; Tabatabaei FS¹ ; Kolahdouzan K² ; Rashidian H³ ; Nourbakhsh F¹ ; Parizi MA¹ ; Darzikolaee NM² ; Bayani R² ; Salarvand S⁴ ; Sharifian A¹ ; Bagheri F¹ ; Rezaei S¹ ; Nabian N¹ ; Nazari R¹ Show All Authors

Azimi A¹
Tabatabaei FS¹
Kolahdouzan K²
Rashidian H³
Nourbakhsh F¹
Parizi MA¹
Darzikolaee NM²
Bayani R²
Salarvand S⁴
Sharifian A¹
Bagheri F¹
Rezaei S¹
Nabian N¹
Nazari R¹
Mohammadi N¹
Babaei M¹
Lashkari M¹
Farhan F²
Aghili M¹
Counago F⁵
Gambacorta MA⁶
Ghalehtaki R^{1, 2, 7}

Show Affiliations

1. Radiation Oncology Research Center, Cancer Research Institute, Tehran University of Medical Sciences, Tehran, Iran
2. Department of Radiation Oncology, Cancer Institute, School of Medicine, IKHC, Tehran University of Medical Sciences, Tehran, Iran
3. Cancer Research Center, Cancer Research Institute, Tehran University of Medical Sciences, Tehran, Iran
4. Department of Anatomical and Clinical Pathology, School of Medicine, IKHC, Tehran University of Medical Sciences, Tehran, Iran
5. Department of Radiation Oncology, Hospital Universitario Vithas Madrid La Milagrosa, GenesisCare, Madrid, Spain
6. Department of Radiology, Radiation Oncology and Hematology, Catholic University of the Sacred Heart, Agostino Gemelli University Hospital Foundation IRCCS, Roma, 00168, Italy
7. Radiation Oncology Research Center, Radiation Oncology Ward, Cancer Institute, IKHC, Qarib Street, Tehran, Iran

Source: Radiation Oncology Published:2024

Abstract

Background/Aim: Current approaches for locally advanced rectal cancer (LARC) typically recommend neoadjuvant chemoradiotherapy (nCRT) with 5-fluorouracil (5FU) or its oral analogs followed by surgery as the standard of care. However, the question of whether intensifying concurrent chemotherapy by adding oxaliplatin to the 5FU-based backbone can yield better outcomes remains unresolved. This study aimed to investigate the benefits of incorporating oxaliplatin into fluoropyrimidine-based chemoradiotherapy (CRT) to increase locoregional control and survival. Methods: Among 290 patients with LARC admitted to the Iran Cancer Institute’s radiation oncology department between January 2008 and December 2019, 29 received CAPEOX (capecitabine 625 mg/m²/bid on RT days and weekly oxaliplatin 50 mg/m²), whereas 293 received capecitabine (825 mg/m² twice daily or rarely 5FU in the first 4 days and last week of radiotherapy (RT)). Variables potentially affecting treatment outcomes were used for propensity score matching. Kaplan‒Meier and log-rank tests were employed for overall survival (OS) and disease-free survival (DFS) analyses and were adjusted with propensity score matching. Results: Data from 29 patients who received CAPEOX and 216 patients who received capecitabine were analyzed after propensity score matching without replacement. After propensity score matching, in the multivariate analysis, CAPEOX significantly increased the likelihood of achieving a pathologic complete response (pCR) by 4.38 times (CI: 1.90–10.08, p value < 0.001). However, CAPEOX did not demonstrate any statistically significant predictive value for DFS (P = 0.500) or OS (P = 0.449). Conclusion: The addition of oxaliplatin resulted in a significantly higher rate of pCR without any translation into long-term survival outcomes. © The Author(s) 2024.

Related Docs

View other Related Docs

1. Role of Oxaliplatin in the Neoadjuvant Concurrent Chemoradiotherapy in Locally Advanced Rectal Cancer: A Review of Evidence, Clinical Medicine Insights: Oncology (2024)

2. Outcomes of Neoadjuvant Chemoradiotherapy in T4 Rectal Cancer Patients: A Real-World Single Institution Experience, Radiation Oncology Journal (2024)

3. Current Approaches in Intensification of Long-Course Chemoradiotherapy in Locally Advanced Rectal Cancer: A Review, Radiation Oncology Journal (2021)

4. Short-Course Versus Long-Course Neoadjuvant Chemoradiotherapy in Patients With Rectal Cancer: Long-Term Results of a Randomized Controlled Trial, International Journal of Colorectal Disease (2025)

5. Optimal Sequence for Total Neoadjuvant Therapy in Locally Advanced Rectal Cancer: An Evidence-Based Review, Cancer Medicine (2024)

6. Short-Course Versus Long-Course Neoadjuvant Chemoradiotherapy in Patients With Rectal Cancer: Preliminary Results of a Randomized Controlled Trial, Radiation Oncology Journal (2020)

7. Implications for Pelvic Lymph Node Irradiation in Definitive Chemoradiotherapy of Node Negative Muscle Invasive Bladder Cancer Based on Predictive Factors of Clinicopathologic Discrepancy, Journal of Cancer Research and Clinical Oncology (2023)

8. Neo-Adjuvant Chemoradiotherapy Response Prediction Using Mri Based Ensemble Learning Method in Rectal Cancer Patients, Physica Medica (2019)

Experts (# of related papers)

View all Related Experts

Mahdi Aghili (7)

Reza Ghalehtaki (7)

Style	Citing Format
MLA	Azimi A, et al.. "Short-Term and Long-Term Oncological Outcomes of Chemoradiotherapy for Rectal Cancer Patients With or Without Oxaliplatin: A Propensity Score-Matched Retrospective Analysis." Radiation Oncology, vol. 19, no. 1, 2024, pp. -.
APA	Azimi A, Tabatabaei FS, Kolahdouzan K, Rashidian H, Nourbakhsh F, Parizi MA, Darzikolaee NM, Bayani R, Salarvand S, Sharifian A, Bagheri F, Rezaei S, Nabian N, Nazari R, Mohammadi N, Babaei M, Lashkari M, Farhan F, Aghili M, ... Ghalehtaki R (2024). Short-Term and Long-Term Oncological Outcomes of Chemoradiotherapy for Rectal Cancer Patients With or Without Oxaliplatin: A Propensity Score-Matched Retrospective Analysis. Radiation Oncology, 19(1), -.
Chicago	Azimi A, Tabatabaei FS, Kolahdouzan K, Rashidian H, Nourbakhsh F, Parizi MA, Darzikolaee NM, et al.. "Short-Term and Long-Term Oncological Outcomes of Chemoradiotherapy for Rectal Cancer Patients With or Without Oxaliplatin: A Propensity Score-Matched Retrospective Analysis." Radiation Oncology 19, no. 1 (2024): -.
Harvard	Azimi A et al. (2024) 'Short-Term and Long-Term Oncological Outcomes of Chemoradiotherapy for Rectal Cancer Patients With or Without Oxaliplatin: A Propensity Score-Matched Retrospective Analysis', Radiation Oncology, 19(1), pp. -.
Vancouver	Azimi A, Tabatabaei FS, Kolahdouzan K, Rashidian H, Nourbakhsh F, Parizi MA, et al.. Short-Term and Long-Term Oncological Outcomes of Chemoradiotherapy for Rectal Cancer Patients With or Without Oxaliplatin: A Propensity Score-Matched Retrospective Analysis. Radiation Oncology. 2024;19(1):-.
BibTex	@article{ author = {Azimi A and Tabatabaei FS and Kolahdouzan K and Rashidian H and Nourbakhsh F and Parizi MA and Darzikolaee NM and Bayani R and Salarvand S and Sharifian A and Bagheri F and Rezaei S and Nabian N and Nazari R and Mohammadi N and Babaei M and Lashkari M and Farhan F and Aghili M and Counago F and Gambacorta MA and Ghalehtaki R}, title = {Short-Term and Long-Term Oncological Outcomes of Chemoradiotherapy for Rectal Cancer Patients With or Without Oxaliplatin: A Propensity Score-Matched Retrospective Analysis}, journal = {Radiation Oncology}, volume = {19}, number = {1}, pages = {-}, year = {2024} }
RIS	TY - JOUR AU - Azimi A AU - Tabatabaei FS AU - Kolahdouzan K AU - Rashidian H AU - Nourbakhsh F AU - Parizi MA AU - Darzikolaee NM AU - Bayani R AU - Salarvand S AU - Sharifian A AU - Bagheri F AU - Rezaei S AU - Nabian N AU - Nazari R AU - Mohammadi N AU - Babaei M AU - Lashkari M AU - Farhan F AU - Aghili M AU - Counago F AU - Gambacorta MA AU - Ghalehtaki R TI - Short-Term and Long-Term Oncological Outcomes of Chemoradiotherapy for Rectal Cancer Patients With or Without Oxaliplatin: A Propensity Score-Matched Retrospective Analysis JO - Radiation Oncology VL - 19 IS - 1 SP - EP - PY - 2024 ER -

Science Communicator Platform

Authors

Authors Affiliations

Abstract